Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranquillo LTE: Long-term extension study of ritlecitinib in non-segmental vitiligo
jRCT2031230659Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ritlecitinib tosilate in Vitiligo (3 arms), sponsored by Pfizer. Started Mar 2024; status: active, not recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
Vitiligo
Beyond the preview
Go deeper on jRCT2031230659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230659.